# Qiming Venture Partners Managing Partner Alex Zhou Named to 2026 Forbes Midas List

- Link: https://www.thailand-business-news.com/pr-news/qiming-venture-partners-managing-partner-alex-zhou-named-to-2026-forbes-midas-list
- Published: 2026-05-29T11:00:00+07:00
- Author: PR Newswire

SHANGHAI, May 29, 2026 /PRNewswire/ — Forbes has released its 2026 Midas List, the
definitive ranking of the world’s top venture capital investors. Alex Zhou, Managing
Partner at Qiming Venture Partners, debuts at No. 80, recognizing his track record
as a leading China-based investor focused on technology and artificial intelligence.

Known as the "Oscars of venture capital," the Midas List is the most prestigious
benchmark in global venture capital. The 2026 list marks its 25th anniversary, with
intensified competition across the industry. Surging valuations for frontier companies
including SpaceX, OpenAI and Anthropic have brought 25 new entrants to this year’s
ranking.

Alex Zhou joined Qiming Venture Partners in 2014 and was promoted to Managing Partner
in May 2024. He brings over 20 years of combined operational, entrepreneurial and
investment experience, with a long-term focus on frontier technologies. He is one
of the most active investors backing transformative AI and robotics startups globally.

Alex Zhou has delivered strong exit momentum in 2026. In the first five months of
the year, four of his portfolio companies — Biren Technology, Zhipu AI, Axera Semiconductor
and Viewtrix Technology — have completed public listings.

Alex Zhou adopts a pragmatic "half-step ahead" investment approach for tech and 
AI. Within his core areas of expertise, he identifies early industry inflection 
points and builds positions ahead of mainstream trends, avoiding speculative market
hype. This forward-looking strategy has enabled him to capture outsized returns 
amid major technological paradigm shifts.

In late 2019, when China’s domestic GPU ecosystem remained immature and AI computing
power was yet to gain widespread market recognition, Alex Zhou invested in Biren
Technology at its founding. He led the company’s seed round and continued to support
subsequent financings, helping the firm grow into the first Hong Kong-listed GPU
company.

Alex Zhou made another early, high-impact bet on foundational AI in early 2022. 
At the time, large language models were still an emerging technology, and few investors
recognized their commercial potential. His investment in Zhipu AI supported the 
development of the company’s first-generation GLM model, laying the foundation for
its core technology development.

Alex Zhou’s early-stage focus also extends to embodied intelligence. He backed UBTECH
Robotics eleven years ago and, in the current wave of embodied AI development, has
led investments in a new batch of full-stack robotics companies integrating models
and hardware, including TARS, Dexmal, GalaxyBot and ACE Robotics.

Founded in 2006, Qiming Venture Partners manages 11 USD funds and seven RMB funds,
with $9.5 billion in assets under management. The firm focuses on two core pillars—
technology and healthcare — forming a stable dual-driven investment strategy.

Qiming Venture Partners has maintained a long-term AI investment layout for over
a decade. Starting with deep learning-focused investments in 2013, the firm has 
deployed more than RMB 12 billion into over 100 AI projects across the full industrial
value chain, establishing itself as one of the most active and influential AI investors
in China and Asia. The firm’s investment roadmap follows technological evolution
across LLMs, multimodal AI and embodied intelligence, rather than short-term market
trends.

In healthcare, Qiming Venture Partners is one of China’s earliest institutional 
investors dedicated to the sector. Over the past two decades, its healthcare team
has invested in nearly 200 companies covering innovative pharmaceuticals, innovative
medical devices, AI healthcare applications and other related areas. Its continuous
investment has driven innovation in China’s life sciences industry and delivered
practical clinical value globally.

Qiming Venture Partners’ technology and healthcare practices complement and empower
one another. The firm’s healthcare industry expertise supports its judgments on 
AI+ healthcare applications opportunities, while its frontier tech insights help
identify disruptive technology-driven healthcare startups. This cross-sector synergy
forms Qiming Venture Partners’ key institutional advantage.

Qiming Venture Partners’ recurring recognition on the Midas List across technology,
healthcare and AI reflects its long-built institutional capabilities: consistent
focus on core sectors, proactive early deployment, and full-cycle investment expertise
covering early to growth-stage companies.

Across both core verticals, Qiming Venture Partners executes systematic layout years
before market consensus emerges, partnering with founders for long-term growth and
achieving steady exit results. 

"For the next two decades, AI will stand as the most certain investment opportunity
in China’s venture landscape," said Duane Kuang, Founding Managing Partner of Qiming
Venture Partners. The firm’s healthy cycle of fundraising, investment, portfolio
management and exits continues to validate this long-term judgment.

**About Qiming Venture Partners**

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners 
manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital 
raised. Since our establishment, we have invested in outstanding companies in the
Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. 
Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE,
NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&
A or other means. There are also over 80 portfolio companies that have achieved 
unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective
sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology,
UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee
Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical,
Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine,  AusperBio, Yuanxin Technology,
Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Qiming Venture Partners Managing Partner Alex Zhou Named to 2026 Forbes Midas List ](http://www.prnasia.com/story/archive/4970115_AE70115_0?rand=184833)
